{"pub": "yahoo", "url": "https://news.yahoo.com/abbott-sanofi-team-up-to-help-diabetes-patients-with-new-tech-050145488.html", "downloaded_at": "2019-10-12 00:39:26.932367+00:00", "title": "Abbott, Sanofi to help diabetes patients with technology team-up", "language": "en", "text": "Abbott (ABT) and Sanofi (SNY) announced on Monday a partnership to integrate technology that will help monitor and treat diabetes.\n\nThe agreement is non-exclusive, and will allow for data sharing \u2014 with user consent \u2014 between Abbott\u2019s FreeStyle Libre mobile app and Sanofi\u2019s cloud-connected insulin pens.\n\nThe devices, which will sense glucose levels and deliver insulin, is the latest in a series of cooperative approaches among pharmaceutical companies to specialized markets. Abbott has already engaged with Bigfoot and Novo Nordisk (NOV), another major player in diabetes management.\n\nA device for measuring blood glucose on a white isolated background. More\n\nIn a statement, Jared Watkin, senior vice president of diabetes care at Abbott, said that the company expects \u201ca significant opportunity to impact the health of millions of people living with diabetes\u201d with the new tools.\n\n\u201cBy partnering with Abbott, we are a step closer to realizing our connected ecosystem, which would help improve control and the quality of life decision cycle for patients through individualized glycemic management of diabetes,\u201d said Gustavo Pesquin, senior vice president of global diabetes and cardiovascular franchise at Sanofi.\n\nMore than 30 million Americans are living with diabetes today, according to the Center for Disease Control. The Abbott-Sanofi partnership is a new example of how smart devices are increasingly used for health care purposes \u2014 and to lessen costs.\n\nInsulin injection needle or pen for use by diabetics More\n\nThe American Diabetes Association estimates costs related to diabetes care are in excess of $237 billion in 2017, and an average of $16,475 health care dollars is spent per person each year.\n\nMeanwhile, the price of insulin has been soaring. Families have reported rationing the doses in order to make each refill last, which can have fatal consequences.\n\nIt was unclear whether the Abbott-Sanofi partnership could address insulin rationing. However, Sanofi has previously said it will reduce the medication\u2019s price for patients who are uninsured.\n\nYahoo Finance's All Markets Summit, Oct. 10 More\n\nAnjalee Khemlani is a reporter at Yahoo Finance. Follow her on Twitter: @AnjKhem\n\nRead the latest financial and business news from Yahoo Finance\n\nFollow Yahoo Finance onTwitter,Facebook,Instagram,Flipboard,SmartNews,LinkedIn, YouTube, and reddit.", "description": "Abbott and Sanofi announce a new collaboration to help diabetes patients.", "authors": ["Anjalee Khemlani", "Senior Reporter"], "top_image": "https://s.yimg.com/uu/api/res/1.2/eEt2p8ksJfiacurlabNugw--~B/aD00MDAwO3c9NjAwMDtzbT0xO2FwcGlkPXl0YWNoeW9u/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-images/2019-09/0066b5a0-d636-11e9-9b1f-5359610294f5", "published_at": "2019-09-16"}